Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

被引：0

作者：

Laura A. Huppert ^{[1
]}

Reshma Mahtani ^{[2
]}

Samantha Fisch ^{[1
]}

Naomi Dempsey ^{[2
]}

Sarah Premji ^{[3
]}

Angelina Raimonde ^{[4
]}

Saya Jacob ^{[1
]}

Laura Quintal ^{[1
]}

Michelle Melisko ^{[1
]}

Jo Chien ^{[1
]}

Ana Sandoval ^{[2
]}

Lauren Carcas ^{[2
]}

Manmeet Ahluwalia ^{[2
]}

Natasha Harpalani ^{[2
]}

Jenna Hoppenworth ^{[3
]}

Anne Blaes ^{[5
]}

Kelly Blum ^{[1
]}

Mi-Ok Kim ^{[1
]}

Dame Idossa ^{[5
]}

Ruta Rao ^{[4
]}

Karthik V. Giridhar ^{[3
]}

Hope S. Rugo ^{[1
]}

机构：

[1] San Francisco,University of California

[2] Baptist HealthSouth Florida,Miami Cancer Institute

[3] Rochester,Mayo Clinic

[4] Rush,undefined

[5] University of Minnesota,undefined

来源：

npj Breast Cancer | / 11卷 / 1期

关键词：

D O I：

10.1038/s41523-025-00748-5

中图分类号：

学科分类号：

摘要：

Antibody drug conjugates (ADCs) have improved outcomes for patients with metastatic breast cancer (MBC), but there is little data about the sequential use of these agents. In this multicenter retrospective cohort study, we identified 84 patients with HER2-low MBC treated sequentially with trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in either order at 5 institutions between 2020–2024. We evaluated clinical parameters associated with time to treatment failure (TTF) and real-world overall survival (rwOS). Median TTF was longer for ADC1 than ADC2, irrespective of HR-status, ADC sequence order, age ≤65 or >65 years, presence of visceral disease, or use of an intervening therapy. Younger age, longer time from MBC diagnosis to start of ADC1, and receipt of SG as ADC1 were associated with longer rwOS from start of ADC1. This cohort represents one of the first multicenter retrospective series of patients treated with sequential ADCs for HER2-low MBC, which may inform clinical practice.

引用

共 50 条

[21] Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Guarneri, Valentina
Coelho, Jose Luis Passos
Duhoux, Francois P.
Egle, Daniel
Garcia-Saenz, Jose angel
Penault-Llorca, Frederique
Selander, Katri
Wildiers, Hans
Zaman, Khalil
Laeis, Petra
Lucerna, Markus
Pierga, Jean-Yves
FUTURE ONCOLOGY, 2024, 20 (18) : 1237 - 1250
[22] Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
Vaz Batista, M.
Perez-Garcia, J. M.
Llombart Cussac, A.
Cortez, P.
Ruiz Borrego, M.
De la Haba, J.
Cejalvo, J. M.
Racca, F.
Servitja, S.
Blanch, S.
Lema, L.
Galan Garmaje, M.
Fernandez-Abad, M.
Fernandez, A.
Iranzo, V.
Gonzalez-Santiago, S.
Gion, M.
Nave, M.
Cortes, J.
Braga, S.
ANNALS OF ONCOLOGY, 2021, 32 : S509 - S510
[23] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Modi, S.
Jacot, W.
Iwata, H.
Park, Y. H.
Vidal Losada, M. J.
Li, W.
Tsurutani, J.
Zaman, K.
Ueno, N. T.
Prat, A.
Papazisis, K.
Rugo, H. S.
Harbeck, N.
Im, S-A.
De Laurentiis, M.
Orbegoso, C. M. A.
Yung, L.
Cheng, F-C.
Cheng, Y.
Cameron, D. A.
ANNALS OF ONCOLOGY, 2023, 34 : S334 - S335
[24] ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
Meng, Y.
Mu, Y.
Zhang, J.
ANNALS OF ONCOLOGY, 2024, 35 : S402 - S402
[25] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
Hamilton, Erika P.
Hurvitz, Sara A.
Im, Seock-Ah
Iwata, Hiroji
Curigliano, Giuseppe
Kim, Sung-Bae
Chiu, Joanne Wing-Yan
Pedrini, Jose Luiz
Li, Wei
Yonemori, Kan
Bianchini, Giampaolo
Loi, Sherene
Borges, Giuliano Santos
Wang, Xian
Bachelot, Thomas
Nakatani, Shunsuke
Ashfaque, Shahid
Liang, Zhengkang
Egorov, Anton
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
Lin, N.
Ciruelos, E. M.
Jerusalem, G.
Mueller, V.
Niikura, N.
Viale, G.
Bartsch, R.
Kurzeder, C.
Connolly, R.
Baron-Hay, S. E.
Cortes, M. Gion
Guarneri, V.
Bianchini, G.
Wildiers, H.
Escriva-de-Romani, S.
Prahladan, M.
Bridge, H.
Verma, S.
Harbeck, N.
ANNALS OF ONCOLOGY, 2024, 35 : 1211 - 1212
[27] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Cortes, J.
Kim, S-B.
Chung, W-P.
Im, S-A.
Park, Y. H.
Hegg, R.
Kim, M. H.
Tseng, L-M.
Petry, V.
Chung, C-F.
Iwata, H.
Hamilton, E.
Curigliano, G.
Xu, B.
Lee, C.
Liu, Y.
Cathcart, J.
Bako, E.
Verma, S.
Hurvitz, S. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1287 - S1288
[28] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Saura Manich, C.
Modi, S.
Krop, I.
Park, Y. H.
Kim, S-B.
Tamura, K.
Andre, F.
Iwata, H.
Ito, Y.
Tsurutani, J.
Sohn, J.
Lee, C.
Liu, Y.
Cathcart, J.
Singh, J.
Yamashita, T.
ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
[29] Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer
Tsao, Li-Chung
Wang, John S.
Ragusa, Joey
Liu, Bushangqing
McBane, Jason
Spasojevic, Ivan
Fan, Ping
Trotter, Timothy N.
Lyerly, Herbert Kim
Hartman, Zachary C.
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
[30] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
Ueno, N. T.
Jacot, W.
Yamashita, T.
Sohn, J.
Tokunaga, E.
Prat, A.
Tsurutani, J.
Park, Y. H.
Rugo, H. S.
Xu, B.
Cardoso, F.
Mitri, Z.
Mahtani, R.
Dunton, K.
Wang, Y.
Gambhire, D.
Cottone, F.
Harbeck, N.
Cameron, D. A.
Modi, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633

← 1 2 3 4 5 →